Quantcast

Latest Gilead Sciences Stories

2014-08-22 16:23:16

LONDON, Aug. 22, 2014 /PRNewswire/ -- ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq(®) (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.(1) Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside...

2014-08-21 12:29:02

CHICAGO, Aug. 21, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report), Amgen (Nasdaq:AMGN-Free Report), Roche (OTC:RHHBY-Free Report) and Biogen (Nasdaq:BIIB-Free Report)....

2014-08-08 08:25:05

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, August 8, 2014 /PRNewswire/ -- Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Express Scripts Holding Company (NASDAQ: ESRX) and Tenet Healthcare Corp. (NYSE: THC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are...

2014-08-07 12:32:19

CHICAGO, Aug. 7, 2014 /PRNewswire/ -- Zacks Director of Research Sheraz Mian says, "The reduced negative revisions rate at this stage in the reporting cycle is the most notable positive element of this earnings season." http://photos.prnewswire.com/prnvar/20101027/ZIRLOGO Q3 Earnings Estimates Not Falling As Much The Q2 earnings season has turned out to be better relative to other recent reporting periods - the growth rate is better, more companies are beating estimates, and the very modest...

2014-08-01 12:28:49

CHICAGO, Aug. 1, 2014 /PRNewswire/ -- Zacks Director of Research Sheraz Mian says, "The overall picture emerging from the ongoing Q2 earnings season is notably better relative to what has been on offer in the recent past" http://photos.prnewswire.com/prnvar/20101027/ZIRLOGO Can the Earnings Rebound be Sustained? The overall picture emerging from the ongoing Q2 earnings season is notably better relative to what has been on offer in the recent past - growth is improving, more companies are...

2014-07-31 08:37:23

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, July 31, 2014 /PRNewswire/ -- Today, Analysts Review released its research reports regarding AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Horizon Pharma Inc. (NASDAQ: HZNP), Gilead Sciences Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV) and Exelixis Inc. (NASDAQ: EXEL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are...

2014-07-29 23:15:48

Doctor Evidence, LLC has developed a comprehensive database of clinical evidence in Hepatitis C (HCV) to address the evolving needs of healthcare stakeholders. Santa Monica, CA (PRWEB) July 29, 2014 Doctor Evidence (“DRE”), the Santa Monica, California-based healthcare information leader has responded to marketplace clamor related to the transformative innovations in Hepatitis C virus (HCV) treatments with a comprehensive comparative effectiveness database that allows healthcare...

2014-07-28 16:27:12

FLINT, Mich., July 28, 2014 /PRNewswire/ -- Diplomat, the nation's largest independent specialty pharmacy, announced today that it has been selected as a provider of Zydelig(®) tablets. Zydelig was approved by the U.S. Food and Drug Administration on July 23, 2014 for the treatment of three B-cell blood cancers. "We are pleased to partner with Gilead and be included in the limited panel of distribution for Zydelig," said Gary Kadlec, R.Ph, President of Diplomat. "Our expertise in...

2014-07-24 00:21:34

MELBOURNE, Australia, July 24, 2014 /PRNewswire/ -- Announced at the 20th International AIDS Conference in Melbourne, the agreement seeks to increase access to a promising new HIV medicine in 112 developing countries At the AIDS 2014 conference in Melbourne today, the Medicines Patent Pool (MPP) announced a new licensing agreement with Gilead Sciences for tenofovir alafenamide (TAF), a promising new medicine currently...

2014-07-23 12:32:28

CALGARY, July 23, 2014 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today announced that it has appointed Julie Cherrington PhD to act as the President and Chief Executive Officer of Zenith Epigenetics Corp. Julie has an extensive background leading companies focused on the discovery and development of novel cancer therapeutics and is well-versed in the challenges of developing drugs and advancing them into the clinic and through to commercialization. Her...


Word of the Day
caparison
  • A cloth or covering, more or less ornamented, laid over the saddle or furniture of a horse, especially of a sumpter-horse or horse of state.
  • Clothing, especially sumptuous clothing; equipment; outfit.
  • To cover with a caparison, as a horse.
  • To dress sumptuously; adorn with rich dress.
This word ultimately comes from the Medieval Latin 'cappa,' cloak.
Related